» Articles » PMID: 37469014

Generation and Engineering of Potent Single Domain Antibody-based Bispecific IL-18 Mimetics Resistant to IL-18BP Decoy Receptor Inhibition

Abstract

Here, we generated bispecific antibody (bsAb) derivatives that mimic the function of interleukin (IL)-18 based on single domain antibodies (sdAbs) specific to IL-18 Rα and IL-18 Rβ. For this, camelids were immunized, followed by yeast surface display (YSD)-enabled discovery of VHHs targeting the individual receptor subunits. Upon reformatting into a strictly monovalent (1 + 1) bispecific sdAb architecture, several bsAbs triggered dose-dependent IL-18 R downstream signaling on IL-18 reporter cells, as well as IFN-γ release by peripheral blood mononuclear cells in the presence of low-dose IL-12. However, compared with IL-18, potencies and efficacies were considerably attenuated. By engineering paratope valencies and the spatial orientation of individual paratopes within the overall design architecture, we were able to generate IL-18 mimetics displaying significantly augmented functionalities, resulting in bispecific cytokine mimetics that were more potent than IL-18 in triggering proinflammatory cytokine release. Furthermore, generated IL-18 mimetics were unaffected from inhibition by IL-18 binding protein decoy receptor. Essentially, we demonstrate that this strategy enables the generation of IL-18 mimetics with tailor-made cytokine functionalities.

Citing Articles

Taming interleukin-12: Engineering of bispecific antibody-based IL-12 mimetics with biased agonism capacities.

Lipinski B, Unmuth L, Arras P, Endruszeit R, Becker S, Rodel J Protein Sci. 2025; 34(3):e70072.

PMID: 39981925 PMC: 11843475. DOI: 10.1002/pro.70072.


An engineered palivizumab IgG2 subclass for synthetic gp130 and fas-mediated signaling.

Wittich C, Ettich J, Hertell M, Roy B, Ghosh Roy B, Xu H J Biol Chem. 2025; 301(3):108205.

PMID: 39828098 PMC: 11872477. DOI: 10.1016/j.jbc.2025.108205.


IL-18 and IL-18BP: A Unique Dyad in Health and Disease.

Novick D Int J Mol Sci. 2025; 25(24.

PMID: 39769266 PMC: 11727785. DOI: 10.3390/ijms252413505.


On the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality.

Fernandez-Quintero M, Guarnera E, Musil D, Pekar L, Sellmann C, Freire F Protein Sci. 2024; 33(11):e5176.

PMID: 39422475 PMC: 11487682. DOI: 10.1002/pro.5176.


The present and future of bispecific antibodies for cancer therapy.

Klein C, Brinkmann U, Reichert J, Kontermann R Nat Rev Drug Discov. 2024; 23(4):301-319.

PMID: 38448606 DOI: 10.1038/s41573-024-00896-6.


References
1.
Markham A . Envafolimab: First Approval. Drugs. 2022; 82(2):235-240. DOI: 10.1007/s40265-022-01671-w. View

2.
de Jong R, Beurskens F, Verploegen S, Strumane K, van Kampen M, Voorhorst M . A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface. PLoS Biol. 2016; 14(1):e1002344. PMC: 4703389. DOI: 10.1371/journal.pbio.1002344. View

3.
Saxton R, Glassman C, Garcia K . Emerging principles of cytokine pharmacology and therapeutics. Nat Rev Drug Discov. 2022; 22(1):21-37. PMC: 10292932. DOI: 10.1038/s41573-022-00557-6. View

4.
Amin A, White R . Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?. J Kidney Cancer VHL. 2017; 1(7):74-83. PMC: 5345537. DOI: 10.15586/jkcvhl.2014.18. View

5.
Yen M, Ren J, Liu Q, Glassman C, Sheahan T, Picton L . Facile discovery of surrogate cytokine agonists. Cell. 2022; 185(8):1414-1430.e19. PMC: 9021867. DOI: 10.1016/j.cell.2022.02.025. View